Form 8-K - Current report:
SEC Accession No. 0001193125-25-072397
Filing Date
2025-04-03
Accepted
2025-04-03 16:27:36
Documents
13
Period of Report
2025-03-31
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d945844d8k.htm   iXBRL 8-K 22749
  Complete submission text file 0001193125-25-072397.txt   151665

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apto-20250331.xsd EX-101.SCH 2877
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apto-20250331_lab.xml EX-101.LAB 19468
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apto-20250331_pre.xml EX-101.PRE 12162
16 EXTRACTED XBRL INSTANCE DOCUMENT d945844d8k_htm.xml XML 3974
Mailing Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6
Business Address 66 WELLINGTON STREET WEST, SUITE 5300 TD BANK TOWER BOX 48 TORONTO A6 M5K 1E6 310-849-8060
Aptose Biosciences Inc. (Filer) CIK: 0000882361 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32001 | Film No.: 25809926
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)